Erythroplasia of Queyrat: Difference between revisions
Jump to navigation
Jump to search
| Line 118: | Line 118: | ||
=== Surgery === | === Surgery === | ||
* | *Microscopic shaving (Mohs surgery) can be performed for patients with aggressive forms of Erythroplasia of Queyrat. | ||
=== Prevention === | === Prevention === | ||
*There are no primary preventive measures available for [disease | *There are no primary preventive measures available for [disease | ||
Revision as of 16:11, 14 April 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Your Name
Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3
Overview
Historical Perspective
- [Disease name] was first discovered by [scientist name], a
[nationality + occupation], in [year] during/following [event].
- In [year], [gene] mutations were first identified in the pathogenesis
of [disease name].
- In [year], the first [discovery] was developed by [scientist] to
treat/diagnose [disease name].
Classification
- [Disease name] may be classified according to [classification method]
into [number] subtypes/groups:
- [group1]
- [group2]
- [group3]
- Other variants of [disease name] include [disease subtype 1],
[disease subtype 2], and [disease subtype 3].
Pathophysiology
- The pathogenesis of Erythroplasia of Queyrat is characterized by squamous cell carcinoma in situ of the glans penis[1]
- The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
- On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
- On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
Causes
- [Disease name] may be caused by either [cause1], [cause2], or
[cause3].
- [Disease name] is caused by a mutation in the [gene1], [gene2], or
[gene3] gene[s].
- There are no established causes for [disease name].
Differentiating [disease name] from other Diseases
- [Disease name] must be differentiated from other diseases that cause
[clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
- [Differential dx1]
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics
- The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
- In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
Age
- Patients of all age groups may develop [disease name].
- [Disease name] is more commonly observed among patients aged [age range] years old.
- [Disease name] is more commonly observed among [elderly patients/young patients/children].
Gender
- Males areaffected with Erythroplasia of Queyrat.
Race
- There is no racial predilection for [disease name].
- [Disease name] usually affects individuals of the [race 1] race.
- [Race 2] individuals are less likely to develop [disease name].
Risk Factors
- Most common risk factor in the development of Erythroplasia of Queyrat are uncircumcised penis.
Natural History, Complications and Prognosis
- The majority of patients with [disease name] remain asymptomatic for
[duration/years].
- Early clinical features include [manifestation 1], [manifestation 2],
and [manifestation 3].
- If left untreated, [#%] of patients with [disease name] may progress
to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of [disease name] include [complication 1],
[complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10year
mortality/survival rate] of patients with [disease name] is approximately [#%].
Diagnosis
Diagnostic Criteria
- The diagnosis of [disease name] is made when at least [number] of the
following [number] diagnostic criteria are met:
- [criterion 1]
- [criterion 2]
- [criterion 3]
- [criterion 4]
Symptoms
- Symptoms of Erythroplasia of Queyrat may include the following:
- Red rash on the tip of the penis
- Irritation on the tip of the penis
Physical Examination
- Patients with [disease name] usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- There are no specific laboratory findings associated with [disease
name].
- A [positive/negative] [test name] is diagnostic of [disease name].
- An [elevated/reduced] concentration of
[serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
- Other laboratory findings consistent with the diagnosis of [disease
name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
Imaging Findings
- There are no [imaging study] findings associated with [disease name].
- [Imaging study 1] is the imaging modality of choice for [disease
name].
- On [imaging study 1], [disease name] is characterized by [finding 1],
[finding 2], and [finding 3].
- [Imaging study 2] may demonstrate [finding 1], [finding 2], and
[finding 3].
Other Diagnostic Studies
- [Disease name] may also be diagnosed using [diagnostic study name].
- Findings on [diagnostic study name] include [finding 1], [finding 2],
and [finding 3].
Treatment
Medical Therapy
- The mainstay of therapy for Erythroplasia of Queyrat is imiquimod or 5-fluorouracil for several weeks to months.
Surgery
- Microscopic shaving (Mohs surgery) can be performed for patients with aggressive forms of Erythroplasia of Queyrat.
Prevention
- There are no primary preventive measures available for [disease
name].
- Effective measures for the primary prevention of [disease name]
include [measure1], [measure2], and [measure3].
- Once diagnosed and successfully treated, patients with [disease name]
are followedup every [duration]. Followup testing includes [test 1], [test 2], and [test 3].
References
- ↑ Marks, James G; Miller, Jeffery (2006). Lookingbill and Marks' Principles of Dermatology (4th ed.). Elsevier Inc. Page 63. ISBN 1-4160-3185-5.